Belinostat

Belinostat, a novel HDAC inhibitor, is being evaluated, under a Special Protocol Assessment (SPA), as monotherapy treatment for relapsed or refractory PTCL, an indication for which it has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration (FDA).

unknown title 2011

Belinostat is currently in a registrational, pivotal trial, under an SPA, as monotherapy for relapsed and refractory PTCL, an indication which has been granted Orphan Drug and Fast Track designation by the FDA.

unknown title 2011

Belinostat is also under investigation in a randomized Phase 2 trial, as a combination therapy with carboplatin and paclitaxel, for cancer of unknown primary CUP.

unknown title 2011

Belinostat PXD 101 is a Class I and II HDAC inhibitor that is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers.

unknown title 2011

Belinostat is currently in a registrational trial, the BELIEF Study, under a SPA, as monotherapy for relapsed or refractory PTCL, an indication for which it has been granted Orphan Drug and Fast Track designations by the FDA.

unknown title 2011

Belinostat is the only HDAC inhibitor in clinical development with multiple potential routes of administration, including intravenous administration, continuous intravenous infusion and oral administration.

unknown title 2011

Belinostat is a novel HDAC inhibitor that has the potential to play an important role in therapy for PTCL, an often lethal disease with significant unmet medical need, and in a variety of other indications.

unknown title 2011

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs Amid stalled health reform efforts, advocates emerge for the state-by-state approach National symposium aims to attract more women for a rewarding career in surgery Quark Pharmaceuticals 'QPI-1002 receives orphan drug designation from FDA Embera NeuroTherapeutics establishes clinical development partnership for its cocaine dependence program TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

THE MEDICAL NEWS Editors 2010

Belinostat, a HDAC Inhibitor, is Currently in a Multicenter, Registrational

WN.com - Articles related to New technique shakes brain cancer cells to death 2010

We currently expect to file the New Drug Applications for Belinostat and apaziquone in 2011 and 2012, respectively.

The Earth Times Online Newspaper 2010